Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Oncopeptides presents promising data from the Phase 2 ANCHOR combination study in patients with RRMM at ASH Annual Meeting 2019

STOCKHOLM — December 8, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at the ASH Annual Meeting 2019. In the data presented, melflufen and dexamethasone demonstrated positive efficacy in combination with daratumumab or bortezomib in patients with relapsed/refractory multiple myeloma (RRMM). Preclinical data supporting clinical development of melflufen in AL amyloidosis will also be presented for the first time.Overall Conclusions – ANCHOR Poster Presentation · Patients in the ANCHOR

Results from a survey with patients with immune thrombocytopenia (ITP) demonstrates disease burden and impact for patients with ITP

Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented results from an online survey highlighting disease burden and impact for patients with immune thrombocytopenia (ITP), at the 61st Annual Meeting of the American Society of Hematology (ASH) taking place in Orlando, 7-10 December. Immune thrombocytopenia (ITP) is an autoimmune disorder causing reduced platelet counts <100,000/µL, with potential bleeding consequences and reduced quality of life. Treatment is generally reserved for adults with platelet counts <30,000/µL. ITP patients

Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019

STOCKHOLM — December 7, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting 2019. Melflufen showed an overall response rate (ORR) of 29% and clinical benefit rate (CBR) of 37% in patients with late-stage relapsed/refractory multiple myeloma (RRMM). The safety profile remained consistent with prior reports from the HORIZON study. These data reinforce Oncopeptides’ view that melflufen can play a role in the treatment of patients with RRMM and the Company plans to submit a New Drug Application

Ericsson reaches resolution on U.S. FCPA investigations

· Ericsson has entered into a three-year Deferred Prosecution Agreement (DPA) with the U.S. Department of Justice (DOJ) to resolve criminal charges related to violations of the FCPA.  This relates to accounting violations of the FCPA in five countries including in Djibouti where there is also a charge of bribery. In the agreement, the DOJ agrees to defer the prosecution of those charges and to have them dismissed at the end of the term in exchange for Ericsson complying with the conditions of the DPA. Conditions include a payment by Ericsson of a fine of USD 520,650,432. As part of the

Elekta completes its investment in ViewRay

STOCKHOLM, December 6, 2019 – Elekta AB (EKTA-B.ST) announced today that that it has completed its investment in ViewRay, Inc. (Nasdaq:VRAY), which was announced on December 2, 2019.  Elekta has invested USD 36 M for 11,501,597 shares of common stock of ViewRay, corresponding to approximately 7.6 percent of the outstanding common stock in ViewRay on a fully diluted basis in the underwritten public offering. The price was set at USD 3.13 per share, pursuant to the Elekta’s commitment agreement with ViewRay. # # # For further information, please contact:Oskar Bosson, Global EVP

The prospectus will be published week 50

The prospectus being produced on the basis of the rights issue, announced on November 18, 2019, will be published no earlier than Monday week 50. About Brighter AB (publ) Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on

Intrum extends and increases its Revolving Credit Facility

Intrum has extended the maturity of the Revolving Credit Facility (RCF) with five plus one year and increased the amount from EUR 1.375bn to EUR 1.8bn. The new facility will cater for Intrum’s long-term growth ambition and assures an appropriate liquidity buffer and Intrum’s underwriting capabilities going forward. The new facility will start in January 2020.  - Intrum has increased the number of participating banks with eight new international lenders and also secured improved terms to further match our capital structure ambition. We welcome the additional lending banks to Intrum and we

Investor Report

To view this report in PDF, please click on the following link: http://www.rns-pdf.londonstockexchange.com/rns/1170W_1-2019-12-6.pdf       RBC Covered Bond Programme Monthly Investor Report Calculation Date:                                      10/31/2019     This report contains information regarding assets pledged as security (theCover Pool) in respect of the obligations under the Covered Bonds issued underRBC's Global Covered Bond Programme as of the indicated Calculation Date.  Thecomposition of the Cover Pool will change as Loans are added and removed from

World's largest treehouse restaurant lit up with 13,000 LED lights this festive season

ONE of the top festive light attractions in the UK has enjoyed a magical makeover this Christmas. Multi-award winning visitor attraction The Alnwick Garden in Northumberland, which is set to celebrate its 20th anniversary next year, has just been named as one of the country’s top five best festive light displays by Country Living Magazine. And the innovative company which brought The Alnwick Garden’s spectacular Grand Cascade water fountain light show to life, has also now turned the spotlight on the venue’s world-famous Treehouse restaurant. Marl International has completed the

Trading of own shares as part of employee’s savings scheme

SpareBank 1 SR-Bank ASA has on 06 Desember 2019 purchased 25.000 own shares at an average price of NOK 97,8053. Total holdings of own shares after the purchase is 116.130 shares. The shares were acquired as part of SpareBank 1 SR-Bank’s savings scheme for employees. For more information about the saving scheme reference is made to the stock exchange notice dated 14 March 2019, and the stock exchange notice dated 24 April 2019. As part of SpareBank 1 SR-Bank ASA savings scheme the company will acquire additional shares, up to a number of 75.000, within the end of Desember 2019.

Repurchase of shares in subsidiary by Transcendent Group

In connection with Christina Falk, previous CEO of the subsidiary Transcendent Group Väst AB until August 2019, terminating her employment with Transcendent Group, a shareholding corresponding to 19.8 % of the number of shares in Transcendent Group Väst AB is repurchased, at a total amount of SEK 1.6 million. After the repurchase, Transcendent Group AB owns 80.2% in Transcendent Group Väst AB. After a reorganization during the summer Martin Bohlin is the CEO of Transcendent Group Väst AB. The transaction and transfer of shares will take place during the week commencing December 9,

California Hotel & Lodging Association Honored for Excellence in Communications

Austin, Texas – The California Hotel & Lodging Association (CHLA) is the recipient of the 2019 International Society of Hotel Associations (ISHA) Awards of Excellence for Communications.  The awards were presented on Thursday, December 5, 2019 at the annual ISHA Winter Conference at the Kimpton Hotel Van Zandt in Austin, TX. Jennifer Flohr, CAE, CMP, Senior Vice President and Sandra Oberle, Senior Membership Manager accepted the award on behalf of CHLA.   The Award of Excellence in communications is awarded to an association with “a program or project that positively impacts the

DNB ASA - Share buy-back status after week 49

During week 49 2019, DNB has purchased 1 496 000 own shares at an average price of NOK 153.69 per share. After this, DNB ASA owns a total of 7 258 000 own shares. The repurchase of shares is part of the share buy-back programme announced by DNB ASA on 24 October 2019, as subsequently amended by an announcement on 20 November 2019. The share buy-back programme comprises up to approximately 15.8 million shares, of which up to approximately 10.4 million shares may be repurchased in the open market. The rest will be redeemed from the state of Norway on a proportionate basis, subject to

Svensk Hypotekspension AB – Issuance of new notes and early redemption of notes by wholly-owned subsidiaries

The wholly-owned subsidiary Svensk Hypotekspension Fond 4 AB (publ) (“SHP 4”) of Svensk Hypotekspension AB (“SHP”) intends to issue mortgage backed fixed rate notes with ISIN SE0013513371 in the total amount of SEK 2,250,000,000 with final maturity in December 2067 (the “New Notes”). The issue date for the New Notes will be 17 December 2019. The New Notes will have a fixed interest rate of 1.50 per cent. per annum. The first call date will be 22 January 2024. The New Notes are expected to receive an A+ sf rating by Fitch Ratings Ltd. SHP 4 intends to apply for admission to trading of the

#19-1154 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

Sofie Zettergren, CFO of Storytel, takes parental leave – Jörgen Gullbrandson assumes the position of interim CFO

Sofie Zettergren, Chief Financial Officer of Storytel, takes parental leave in February 2020. During the leave, Jörgen Gullbrandson will assume the position of interim CFO of Storytel. Jörgen Gullbrandson has solid knowledge of Storytel’s business areas, and comprehensive experience from over 10 years as CFO in companies focusing on recurring revenue. Jörgen Gullbrandson joins Storytel after a recent position at Readly, a digital subscription service for newspapers and magazines.  FNCA Sweden AB is the Company’s Certified Adviser. FNCA can be reached at info@fnca.se and +46 8 528 00 399.

Acquisition of Colegio Inglés Zaragoza

Internationella Engelska Skolan i Sverige Holdings II AB (”Internationella Engelska Skolan” or ”IES”) has through its wholly-owned Spanish subsidiary International Education Partnership S.L (”IEP”) signed an agreement to acquire the school operations of Colegio Inglés Zaragoza, a private school in Zaragoza, Spain. Colegio Inglés Zaragoza has 270 students aged from 3 to 16 years. It is a fee-paying bilingual private school which follows the Spanish curriculum. The school is located in the city of Zaragoza which is the fifth largest city in Spain. Anna Sörelius Nordenborg, CEO of

Transcendent Group’s interim CEO for RegTech appointed permanent CEO of the subsidiary

Transcendent Group AB (publ), a leading expert within Governance, Risk and Compliance has appointed Magnus Karlsson as the permanent CEO for the subsidiary Transcendent Group Regulatory Technology (RegTech). Magnus Karlsson most recent position has been the interim CEO of RegTech and Chief Operating Officer in Transcendent Group.”I am glad that Magnus, who has made an impressive impression among the management team in the role as interim CEO, now will become permanent CEO of RegTech. Magnus has extensive experience from our operations and services, and thereby excellent insights on the

Publication of Base Prospectus Supplement

Investec Bank plcIncorporated in England and WalesRegistration number 489604   Date: 06 December 2019   Publication of Base Prospectus Supplement The following document has been approved by the United Kingdom Financial Conduct Authority and is available for viewing: Base Prospectus Supplement dated 05 December 2019 relating to Investec Bank plc's (i) Base Prospectus dated 17 July 2019 relating to the £4,000,000,000 Zebra Capital Plans Retail Structured Products Programme; and (ii) Base Prospectus dated 17 July 2019 relating to the £2,000,000,000 Impala Bonds Programme.

Nomination Committee proposes Alf Göransson as new Chairman of NCC

NCC’s Nomination Committee has proposed Alf Göransson to be elected as the new Chairman of the Board of NCC at the next Annual General Meeting, which will be held on April 1, 2020. Current Chairman, Tomas Billing, has declined reelection. Alf Göransson is Chairman of the Board of Loomis and Axfast. He is Board member of Sweco, Attendo, Hexpol, Melker Schörling AB and Sandberg Development Group. Previous experience includes positions as President and CEO of NCC between 2001 and 2007 and President and CEO of Securitas between 2007 and 2018. He has been a member of the NCC Board

Read original

Starbreeze has successfully completed the company reconstruction process, Stockholm District Court approved the composition proposal

STOCKHOLM (December 6, 2019) - The Stockholm District Court has today approved the composition proposal regarding Starbreeze's company reconstruction. Starbreeze, which has been in reconstruction since 3 December 2018, has now successfully completed the process. "Today, we are delighted and proud to announce that we have successfully completed the reconstruction process," said Mikael Nermark, acting CEO Starbreeze AB. “It has been a toilsome journey for the entire company over the past twelve months, but we are very pleased to have gained the creditors’ confidence and have succeeded in

BAKKAFROST – Final results of the Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, WHETHER IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG, KONG, JAPAN, THE UNITED STATES, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.The subscription period for the subsequent offering (the “Subsequent Offering”) in P/F Bakkafrost (“Bakkafrost”) expired on 5 November 2019 at 16:30 hours (CET). The final allocation of the new shares in the Subsequent Offering has

Oncopeptides will host a webcast on Tuesday, December 10[th] at 13:00 (CET) to provide an update regarding data presented at the ASH annual meeting

Stockholm – December 6, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will host a webcast on Tuesday, December 10th, 2019, at 13:00 (CET) to provide an update regarding  the data presented  December 7-8 at the American Society Hematology (ASH) Annual Meeting 2019. The webcast will be hosted by CEO Jakob Lindberg.The webcast can be followed via the link: https://tv.streamfabriken.com/oncopeptides-webcast-post-ash Participants who would like to ask questions can use the telephone numbers below: Sweden: + 46 8 56642706Europe: + 44 3333009270USA:

Clinical results for Episealer® accepted as poster presentation for the ESSKA Congress

Episurf Medical (Nasdaq: EPIS B) today announces that a scientific abstract presenting clinical results from the use of the Episealer® implant has been accepted as a poster presentation for the upcoming ESSKA Congress in Milan. The abstract, “Clinical 2 years results after implantation of patient specific mini-metal implants for (osteo-)chondral knee lesions in middle-aged patients after previous frustrane cartilage surgery”, is authored by Priv.-Doz. Dr. med. Clemens Kösters from the Maria-Josef-Hospital Greven in Germany.  ESSKA (European Society for Sports Traumatology, Knee Surgery

There are no items matching the current filter
There are no more items matching the current filter
Back to top